Effect of GLP-1 on Angiogenesis

NCT02686177 on ClinicalTrials.gov · last registry update 2021-06-15

Finished 8 August 2017, after enrolling 50 people. Primary outcome, as filed: Difference of ANGPTL4 concentration at 4 weeks of treatment from baseline in Liraglutide and control group. liraglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Assistance Publique - Hôpitaux de Paris
Sponsor type: Other
Enrollment: 50
Started: 2016-05-18
Primary completion: 2017-08-08 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Difference of ANGPTL4 concentration at 4 weeks of treatment from baseline in Liraglutide and control group

Conditions studied

Type 2 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.